An open-label, multi-centre, post-marketing study to assess the efficacy and safety of a plasma-derived VWF/FVIII concentrate in patients with von Willebrand disease

Haemophilia. 2024 Jan;30(1):236-240. doi: 10.1111/hae.14868. Epub 2023 Nov 29.
No abstract available

Publication types

  • Letter

MeSH terms

  • Factor VIII / adverse effects
  • Humans
  • Patients
  • von Willebrand Diseases* / drug therapy
  • von Willebrand Factor / therapeutic use

Substances

  • von Willebrand Factor
  • Factor VIII

Grants and funding